Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
BackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperur...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/full |
id |
doaj-7d644b67f4034d018c73e65fec6dcc60 |
---|---|
record_format |
Article |
spelling |
doaj-7d644b67f4034d018c73e65fec6dcc602020-12-08T08:40:59ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2020-11-011110.3389/fphys.2020.524236524236Association of Hyperuricemia With Immune Disorders and Intestinal Barrier DysfunctionQiulan Lv0Daxing Xu1Xuezhi Zhang2Xiaomin Yang3Peng Zhao4Xuena Cui5Xiu Liu6Wan Yang7Guanpin Yang8Shichao Xing9Shichao Xing10Shichao Xing11Medical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaThe Key Laboratory of Mariculture, Ministry of Education, Ocean University of China, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaInstitute of Sports Medicine and Health, Qingdao University, Qingdao, ChinaGuy’s & St Thomas’ Hospital, King’s College London, London, United KingdomBackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperuricemia are still unknown.MethodsThis study developed a urate oxidase (Uox)-knockout (Uox–/–) mouse model for hyperuricemia using CRISPR/Cas9 technology. The lipometabolism was assessed by measuring changes in biochemical indicators. Furthermore, 4-kDa fluorescein isothiocyanate–labeled dextran was used to assess gut barrier function. Also, 16S rRNA sequencing was performed to examine the changes in gut microbiota in mouse feces. RNA sequencing, Western blot, Q-PCR, ELISA, and immunohistochemical analysis were used for measuring gene transcription, the number of immune cells, and the levels of cytokines in intestinal tissues, serum, kidney, liver, pancreas, and vascellum.ResultsThis study showed that the abundance of inflammation-related microbiota increased in hyperuricemic mice. The microbial pattern recognition–associated Toll-like receptor pathway and inflammation-associated TNF and NF-kappa B signaling pathways were significantly enriched. The increased abundance of inflammation-related microbiota resulted in immune disorders and intestinal barrier dysfunction by upregulating TLR2/4/5 and promoting the release of IL-1β and TNF-α. The levels of epithelial tight junction proteins occludin and claudin-1 decreased. The expression of the pro-apoptotic gene Bax increased. The levels of LPS and TNF-α in systemic circulation increased in hyperuricemic mice. A positive correlation was observed between the increase in intestinal permeability and serum levels of uric acid.ConclusionHyperuricemia was characterized by dysregulated intestinal immunity, compromised intestinal barrier, and systemic inflammation. These findings might serve as a basis for future novel therapeutic interventions for hyperuricemia.https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/fullhyperuricemiagut microbiotaintestinal immuneintestinal barriersystem inflammation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qiulan Lv Daxing Xu Xuezhi Zhang Xiaomin Yang Peng Zhao Xuena Cui Xiu Liu Wan Yang Guanpin Yang Shichao Xing Shichao Xing Shichao Xing |
spellingShingle |
Qiulan Lv Daxing Xu Xuezhi Zhang Xiaomin Yang Peng Zhao Xuena Cui Xiu Liu Wan Yang Guanpin Yang Shichao Xing Shichao Xing Shichao Xing Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction Frontiers in Physiology hyperuricemia gut microbiota intestinal immune intestinal barrier system inflammation |
author_facet |
Qiulan Lv Daxing Xu Xuezhi Zhang Xiaomin Yang Peng Zhao Xuena Cui Xiu Liu Wan Yang Guanpin Yang Shichao Xing Shichao Xing Shichao Xing |
author_sort |
Qiulan Lv |
title |
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction |
title_short |
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction |
title_full |
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction |
title_fullStr |
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction |
title_full_unstemmed |
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction |
title_sort |
association of hyperuricemia with immune disorders and intestinal barrier dysfunction |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Physiology |
issn |
1664-042X |
publishDate |
2020-11-01 |
description |
BackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperuricemia are still unknown.MethodsThis study developed a urate oxidase (Uox)-knockout (Uox–/–) mouse model for hyperuricemia using CRISPR/Cas9 technology. The lipometabolism was assessed by measuring changes in biochemical indicators. Furthermore, 4-kDa fluorescein isothiocyanate–labeled dextran was used to assess gut barrier function. Also, 16S rRNA sequencing was performed to examine the changes in gut microbiota in mouse feces. RNA sequencing, Western blot, Q-PCR, ELISA, and immunohistochemical analysis were used for measuring gene transcription, the number of immune cells, and the levels of cytokines in intestinal tissues, serum, kidney, liver, pancreas, and vascellum.ResultsThis study showed that the abundance of inflammation-related microbiota increased in hyperuricemic mice. The microbial pattern recognition–associated Toll-like receptor pathway and inflammation-associated TNF and NF-kappa B signaling pathways were significantly enriched. The increased abundance of inflammation-related microbiota resulted in immune disorders and intestinal barrier dysfunction by upregulating TLR2/4/5 and promoting the release of IL-1β and TNF-α. The levels of epithelial tight junction proteins occludin and claudin-1 decreased. The expression of the pro-apoptotic gene Bax increased. The levels of LPS and TNF-α in systemic circulation increased in hyperuricemic mice. A positive correlation was observed between the increase in intestinal permeability and serum levels of uric acid.ConclusionHyperuricemia was characterized by dysregulated intestinal immunity, compromised intestinal barrier, and systemic inflammation. These findings might serve as a basis for future novel therapeutic interventions for hyperuricemia. |
topic |
hyperuricemia gut microbiota intestinal immune intestinal barrier system inflammation |
url |
https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/full |
work_keys_str_mv |
AT qiulanlv associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT daxingxu associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT xuezhizhang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT xiaominyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT pengzhao associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT xuenacui associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT xiuliu associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT wanyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT guanpinyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction |
_version_ |
1724390415537274880 |